Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Other Non Operating Income (2016 - 2026)

Ani Pharmaceuticals' Other Non Operating Income history spans 15 years, with the latest figure at $1.9 million for Q4 2025.

  • On a quarterly basis, Other Non Operating Income rose 240.35% to $1.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.9 million, a 195.98% increase, with the full-year FY2025 number at $1.9 million, up 147.95% from a year prior.
  • Other Non Operating Income hit $1.9 million in Q4 2025 for Ani Pharmaceuticals, up from $1.7 million in the prior quarter.
  • Over the last five years, Other Non Operating Income for ANIP hit a ceiling of $1.9 million in Q4 2025 and a floor of -$2.7 million in Q4 2021.
  • Historically, Other Non Operating Income has averaged -$210888.9 across 5 years, with a median of -$47500.0 in 2022.
  • Biggest five-year swings in Other Non Operating Income: tumbled 5250.0% in 2021 and later skyrocketed 2076.14% in 2025.
  • Tracing ANIP's Other Non Operating Income over 5 years: stood at -$2.7 million in 2021, then soared by 98.44% to -$42000.0 in 2022, then surged by 400.0% to $126000.0 in 2023, then crashed by 1193.65% to -$1.4 million in 2024, then surged by 240.35% to $1.9 million in 2025.
  • Business Quant data shows Other Non Operating Income for ANIP at $1.9 million in Q4 2025, $1.7 million in Q2 2025, and $198000.0 in Q1 2025.